Sigma Of Australia Battle Over Effexor Eyed Closely By Others
This article was originally published in PharmAsia News
Executive Summary
Australia's Sigma Pharmaceutical and its attempts to break loose of Wyeth's Effexor (venlafaxine) antidepressant are being watched closely by other generics makers as Sigma wages its patent battles. Effexor is the best-selling antidepressant in Australia and Sigma has lost its first court challenge to break the patent. Sigma faces two other patents Wyeth claims for the drug. Other generics makers seek to market the drug in Australia where the national health plan shelled out about $80.7 million for it last year. (Click here for more
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.